Three speakers discuss several aspects of CV risk in diabetes: the role for primary care in reducing CV risk factors, the role of GLP-1RAs in reducing CV risk and recommendations in the newest ESC guidelines on diabetes and CVD.
The recommendations in the 2019 ESC guidelines on management of diabetes and CVD have shifted from a glucose-centric approach towards an event-driven approach.
There are barriers to intensify treatment in T2DM patients, leading to poor outcomes. Prof. Khunti presents findings from studies with GLP-1RA as a new, effective treatment option for T2DM patients with high CV risk.
Identifying and treating classic CV risk factors is important in patients with diabetes to reduce their CV risk. In this presentation, prof. Hobbs discusses the classic CV risk factors one by one.